CNS Pharmaceuticals (CNSP) Interest Expenses (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Interest Expenses came in at $2721.0 in Q4 2025, up 975.49% YoY from $253.0 in Q4 2024, and up 28.59% on a QoQ basis from $2116.0 in Q3 2025.
CNS Pharmaceuticals (CNSP) Interest Expenses (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Interest Expenses data on file, last reported at $2721.0 in Q4 2025.
- Quarterly Interest Expenses rose 975.49% year-over-year to $2721.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15230.0 (up 11.99% YoY) and the FY2025 annual result came in at $18.8 million, up 23.02% from the prior year.
- Interest Expenses grew to $2721.0 in Q4 2025, from $2116.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $46248.0 in Q2 2023 to a low of $253.0 in Q4 2024.
- A 5-year average of $5309.9 and a median of $2882.0 in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses jumped 2770.76% — and 2024, when it slumped 91.22%.
- Tracing CNSP's Interest Expenses over 5 years: stood at $2567.0 in 2021, then surged by 31.63% to $3379.0 in 2022, then slipped by 14.74% to $2881.0 in 2023, then tumbled by 91.22% to $253.0 in 2024, then surged by 975.49% to $2721.0 in 2025.
- The last three Interest Expenses figures came in at $2721.0 (Q4 2025), $2116.0 (Q3 2025), and $4185.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | 2,721.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,721.00 |
| Dec 31, 2025 | 2,721.00 |
| Sep 30, 2025 | 2,116.00 |
| Sep 30, 2025 | 2,116.00 |
| Jun 30, 2025 | 4,185.00 |
| Jun 30, 2025 | 4,185.00 |
| Mar 31, 2025 | 6,208.00 |
| Mar 31, 2025 | 6,208.00 |
| Dec 31, 2024 | 253.00 |
| Dec 31, 2024 | 253.00 |
| Sep 30, 2024 | 2,258.00 |
| Sep 30, 2024 | 2,258.00 |
| Jun 30, 2024 | 4,463.00 |
| Jun 30, 2024 | 4,463.00 |
| Mar 31, 2024 | 6,625.00 |
| Mar 31, 2024 | 6,625.00 |
| Dec 31, 2023 | 2,881.00 |
| Dec 31, 2023 | 2,881.00 |
| Sep 30, 2023 | 4,318.00 |
| Sep 30, 2023 | 4,318.00 |